Benzinga | Aug 18, 2020 06:46AM EDT

B of A Securities Initiates Coverage On Inozyme Pharma with Buy Rating, Announces Price Target of $33

B of A Securities analyst Tazeen Ahmad initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Buy rating and announces Price Target of $33.